Evaluation of density of tumor-associated macrophages using CD163 in histological grades of oral squamous cell carcinoma, an immunohistochemical study.
CD163
Epithelial mesenchymal transition(EMT)
tumor microenvironment
tumor-associated macrophages
Journal
Journal of oral and maxillofacial pathology : JOMFP
ISSN: 0973-029X
Titre abrégé: J Oral Maxillofac Pathol
Pays: India
ID NLM: 101227995
Informations de publication
Date de publication:
Historique:
received:
16
03
2020
revised:
11
07
2020
accepted:
28
07
2020
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
11
5
2021
Statut:
ppublish
Résumé
Macrophages account for 30%-50% of the total inflammatory cell population of ''tumor microenvironment'' that plays an important role in cancer metastasis. M2 macrophages are designated as tumor-associated macrophages (TAMs). They are known to orchestrate all the stages of tumor progression. CD163 is TAMs-M2-specific marker. The aim of the study was to evaluate the role of TAMs using CD163 in different histological grades of oral squamous cell carcinoma (OSCC). Expression of CD 163 was investigated in 30 histopthologically diagnosed cases of OSCC. Two sections of 4-μ thickness were stained with hematoxylin and eosin, CD163 (Cell Marque, USA). The expression of TAMs with CD163-positive cells was done by counting the number of macrophages in three high-power fields (×400), and the mean number of macrophages per HPF was evaluated. The statistical analysis was performed using Statistical Software SPSS version 20.0. CD163 TAMs score increasing in higher tumor, node, metastasis stages with significant positive correlation. With higher histological grades, CD163 TAMs score increased. Thus, TAMs may be considered as an independent factor for determining the progression of the tumor. The immunotherapeutic approaches to control M2 TAM numbers could protect against progression to malignancy.
Sections du résumé
BACKGROUND
BACKGROUND
Macrophages account for 30%-50% of the total inflammatory cell population of ''tumor microenvironment'' that plays an important role in cancer metastasis. M2 macrophages are designated as tumor-associated macrophages (TAMs). They are known to orchestrate all the stages of tumor progression. CD163 is TAMs-M2-specific marker.
AIMS
OBJECTIVE
The aim of the study was to evaluate the role of TAMs using CD163 in different histological grades of oral squamous cell carcinoma (OSCC).
SETTING AND DESIGN
METHODS
Expression of CD 163 was investigated in 30 histopthologically diagnosed cases of OSCC.
MATERIALS AND METHODS
METHODS
Two sections of 4-μ thickness were stained with hematoxylin and eosin, CD163 (Cell Marque, USA). The expression of TAMs with CD163-positive cells was done by counting the number of macrophages in three high-power fields (×400), and the mean number of macrophages per HPF was evaluated.
STATISTICAL ANALYSIS
METHODS
The statistical analysis was performed using Statistical Software SPSS version 20.0.
RESULTS
RESULTS
CD163 TAMs score increasing in higher tumor, node, metastasis stages with significant positive correlation.
CONCLUSION
CONCLUSIONS
With higher histological grades, CD163 TAMs score increased. Thus, TAMs may be considered as an independent factor for determining the progression of the tumor. The immunotherapeutic approaches to control M2 TAM numbers could protect against progression to malignancy.
Identifiants
pubmed: 33967504
doi: 10.4103/jomfp.JOMFP_109_20
pii: JOMFP-24-577
pmc: PMC8083437
doi:
Types de publication
Journal Article
Langues
eng
Pagination
577Informations de copyright
Copyright: © 2021 Journal of Oral and Maxillofacial Pathology.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
J Immunol. 2010 Jan 15;184(2):702-12
pubmed: 20018620
Immunol Lett. 2009 Apr 27;123(2):97-102
pubmed: 19428556
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Crit Rev Oncol Hematol. 2008 Apr;66(1):1-9
pubmed: 17913510
Immunology. 2013 Feb;138(2):93-104
pubmed: 23113570
Cancers (Basel). 2011 Sep 28;3(4):3726-39
pubmed: 24213108
Cancer Cell Int. 2013 Apr 03;13(1):31
pubmed: 23552362
Clin Dev Immunol. 2012;2012:948098
pubmed: 22778768
Sci Rep. 2017 May 11;7(1):1755
pubmed: 28496107
J Exp Clin Cancer Res. 2016 Jan 15;35:12
pubmed: 26769084
Ann Maxillofac Surg. 2011 Jul;1(2):150-4
pubmed: 23482819
Am J Clin Pathol. 2004 Nov;122(5):794-801
pubmed: 15491976
Int J Oral Maxillofac Surg. 2019 Oct;48(10):1279-1288
pubmed: 31053518
Biomed Res Int. 2014;2014:838632
pubmed: 24883329
PLoS One. 2013 Nov 18;8(11):e78999
pubmed: 24260143
Chin J Cancer. 2011 Apr;30(4):280-6
pubmed: 21439250
Cell. 2006 Jan 27;124(2):263-6
pubmed: 16439202
Curr Opin Pharmacol. 2009 Aug;9(4):351-69
pubmed: 19665429
J Leukoc Biol. 2009 Nov;86(5):1065-73
pubmed: 19741157
J Oral Maxillofac Pathol. 2013 Jan;17(1):82-8
pubmed: 23798836
BMC Cancer. 2007 Aug 10;7:156
pubmed: 17692120
Oral Dis. 2009 Jan;15(1):8-17
pubmed: 18992016
Am J Transl Res. 2012;4(4):376-89
pubmed: 23145206
J Oral Pathol Med. 2012 Jul;41(6):444-51
pubmed: 22296275